Randi Tobberup1, Lene Thoresen2, Ursula G Falkmer3, Mette K Yilmaz4, Tora S Solheim5, Trude R Balstad5. 1. Center for Nutrition and Bowel Disease, Department of Gastroenterology, Aalborg University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Fredrik Bajers Vej 5, 9100, Aalborg, Denmark. Electronic address: r.tobberup@rn.dk. 2. Cancer Clinic, St. Olavs hospital, Trondheim University hospital, Postboks 3250 Torgarden, NO-7006, Trondheim, Norway; National Advisory Unit on Disease-Related Malnutrition, Oslo University Hospital, Sognsvannsveien 9, 0372, Oslo, Norway. 3. Department of Clinical Medicine, Aalborg University, Fredrik Bajers Vej 5, 9100, Aalborg, Denmark; Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark. 4. Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark. 5. Cancer Clinic, St. Olavs hospital, Trondheim University hospital, Postboks 3250 Torgarden, NO-7006, Trondheim, Norway; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, PO Box 8905, NO-7491, Trondheim, Norway.
Abstract
BACKGROUND: The aim was to evaluate the effects of current parenteral nutrition (PN) treatment on clinical outcomes in patients with advanced cancer. METHODS: This review was conducted according to the PRISMA guidelines (PROSPERO ID: 4201707915). RESULTS: Two underpowered randomized controlled trials and six observational studies were retrieved (n = 894 patients). Health-related quality of life and physical function may improve during anti-neoplastic treatment in who PN treatment is the only feeding opportunity, but not necessarily in patients able to feed enterally. Nutritional status may improve in patients regardless of anti-neoplastic treatment and gastrointestinal function. PN treatment was neither superior to fluid in terminal patients nor to dietary counselling in patients able to feed enterally in regards to survival. The total incidence of adverse events was low. CONCLUSION: Current PN treatment in patients with advanced cancer is understudied and the level of evidence is weak.
BACKGROUND: The aim was to evaluate the effects of current parenteral nutrition (PN) treatment on clinical outcomes in patients with advanced cancer. METHODS: This review was conducted according to the PRISMA guidelines (PROSPERO ID: 4201707915). RESULTS: Two underpowered randomized controlled trials and six observational studies were retrieved (n = 894 patients). Health-related quality of life and physical function may improve during anti-neoplastic treatment in who PN treatment is the only feeding opportunity, but not necessarily in patients able to feed enterally. Nutritional status may improve in patients regardless of anti-neoplastic treatment and gastrointestinal function. PN treatment was neither superior to fluid in terminal patients nor to dietary counselling in patients able to feed enterally in regards to survival. The total incidence of adverse events was low. CONCLUSION: Current PN treatment in patients with advanced cancer is understudied and the level of evidence is weak.
Authors: Markus Kieler; Paul Kössler; Matija Milovic; Elias Meyer; Kristína Križanová; Lea Kum; Alexander Friedrich; Eva Masel; Raimund Bauer; Matthias Unseld Journal: Palliat Med Date: 2022-02-20 Impact factor: 4.762